Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Liver Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Digestive System Neoplasm
Hepatobiliary Neoplasm
Liver Neoplasm

Subtype

Liver Neoplasm

CI-CAN-00001077Explore in graph →

Non-malignant930 active trials14 approved drugs17 evidence items

NCIt: C7103
MeSH: D008113

Overview
Statistics
Survival
Genomics20
Variants & evidence17
Drugs10
Trials4334
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (91)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 30, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 51–75 of 91 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Leonurine inhibits the proliferation and metastasis of liver cancer cells by regulating the PI3K/AKT signaling pathway via epithelial‑mesenchymal transition.
Bowen Hu, Maher Al Hussan, Jiakai Zhang et al. · Mol Med Rep · Sep 1, 2026 · PMID 42429151 · candidate dictionary pubmed
Regulation of tumorigenesis by cellular senescence: Mechanisms and pathways in liver cancer and cholangiocarcinoma.
Tao Lu, Si-Yi Zou, Chang-Sheng Dong et al. · Biochim Biophys Acta Rev Cancer · Sep 1, 2026 · PMID 42419687 · candidate dictionary pubmed
Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response.
Sien Ma, Qianqian Xu, Mengjuan Zhu et al. · Cancer Sci · Sep 1, 2026 · PMID 42393002 · candidate dictionary pubmed
Understanding the Predictors of Self-Perceived Burden in Patients With Liver Cancer.
Bingyang Liu, Dongmei Chu, Kim Lam Soh et al. · Nurs Health Sci · Sep 1, 2026 · PMID 42349868 · candidate dictionary pubmed
Multi-Omics Biomarker Signatures for Precision Diagnosis and Prognosis in Primary Liver Cancer: A Literature Review.
Ke Xu, Yu Liu, Yuan Peng et al. · Biofactors · Jan 1, 2026 · PMID 42697859 · candidate dictionary pubmed
Prediction of Post-Resection Prognosis of HCC According to AFP-PIVKA-II (AP) Score as a Simplified Biomarker of ADV Score: A Validation Analysis Using Korea Liver Cancer Registry Database.
Woo-Hyoung Kang, Shin Hwang, I-Ji Jeong et al. · J Hepatocell Carcinoma · Jan 1, 2026 · PMID 42733464 · candidate dictionary pubmed

Showing 51–75 of 91 publications

← Previous
1
2
3
4
Next →

Reprogramming M2 macrophages via TLR7/8 agonist-loaded hollow MnO2 nanovehicles to suppress the progression of liver cancer.

Pei-Pei He, Zheng-Ju Hou, Han-Mei Li et al. · PLoS One · Jan 1, 2026 · PMID 42758694 · candidate dictionary pubmed

Plant-based Dietary Patterns and the Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver Cancer: A Systematic Review and Meta-analysis.

Matheus Souza, Marcio J M Amaral, Luan C V Lima · J Clin Exp Hepatol · Jan 1, 2026 · PMID 42774737 · candidate dictionary pubmed

Multidisciplinary Treatment for Liver Cancer in China: A Cross-Sectional Survey of Practices, Gaps and Future Directions.

Wei Wang, Wei Jia, Dao-Cheng Zhan et al. · J Hepatocell Carcinoma · Jan 1, 2026 · PMID 42774669 · candidate dictionary pubmed

Comparison of Remimazolam and Propofol for Anesthesia Management in Liver Cancer Patients Undergoing Percutaneous Radiofrequency Ablation: A Randomized Controlled Trial.

Pingping Jiang, Min Deng, Qian Wang et al. · Drug Des Devel Ther · Jan 1, 2026 · PMID 42801141 · candidate dictionary pubmed

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

· Lancet Oncol · 2020 · PMID 32203698 · validated civic_curation pubmed

DNAJB1-PRKACA is specific for fibrolamellar carcinoma.

· Mod Pathol · 2015 · PMID 25698061 · validated civic_curation pubmed

Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma.

· Science · 2014 · PMID 24578576 · validated civic_curation pubmed

Unique genomic profile of fibrolamellar hepatocellular carcinoma.

· Gastroenterology · 2015 · PMID 25557953 · validated civic_curation pubmed

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma.

· Cancer Discov · 2019 · PMID 31575541 · validated civic_curation pubmed

High expression of HEF1 predicts a poorer prognosis of hepatocellular carcinoma: A retrospective study.

· Mol Clin Oncol · 2016 · PMID 26893853 · validated civic_curation pubmed

Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.

· BMC Cancer · 2015 · PMID 26674738 · validated civic_curation pubmed

GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma.

· Neoplasia · 2007 · PMID 17356712 · validated civic_curation pubmed

Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma.

· Br J Cancer · 2019 · PMID 30420614 · validated civic_curation pubmed

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.

· Br J Cancer · 2012 · PMID 22596232 · validated civic_curation pubmed

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

· Clin Cancer Res · 2014 · PMID 25294897 · validated civic_curation pubmed

Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review.

· J Gastrointest Oncol · 2016 · PMID 28078132 · validated civic_curation pubmed

Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing for personalized medicine.

· Ecancermedicalscience · 2014 · PMID 25435907 · validated civic_curation pubmed

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2.

· JCO Precis Oncol · 2024 · PMID 38603650 · validated civic_curation pubmed

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma.

· Oncotarget · 2016 · PMID 26701727 · validated civic_curation pubmed